Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 95

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 95
---
Aggregate Number of Securities to be Purchased Pursuant to Trading ArrangementAggregate Number of Securities to be Sold Pursuant to Trading ArrangementJack Khattar, President, Chief Executive Officer and DirectorYesAdoptedNovember 14, 2024First Transaction Date throughFebruary 24, 2027580,000580,000(2)____________________________________(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).(2) This trading arrangement covers the exercise and sale of stock options, with such sales limited to an amount reasonably estimated such that the net proceeds from the sale are sufficient to cover the exercise cost and taxes associated with the exercise of the stock options.

PART III

ITEM 10.     DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

The information required by this item is incorporated by reference to the similarly named section of our Proxy Statement for our 2025 Annual Meeting to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2024.

ITEM 11.     EXECUTIVE COMPENSATION.

The information required by this item is incorporated by reference to the similarly named section of our Proxy Statement for our 2025 Annual Meeting to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2024.

ITEM 12.     SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The information required by Item 201(d) of Regulation S-K is set forth below. The remainder of the information required by this Item 12 is incorporated by reference to our definitive proxy statement for our 2025 Annual Meeting to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2024.

The following table shows the number of securities that may be issued pursuant to our equity compensation plans (including individual compensation arrangements) as of December 31, 2024:

Equity Compensation Plan InformationPlan categoryNumber of securitiesto be issued uponexercise ofoutstanding options,warrants and rights(1)Weighted-average exerciseprice of outstandingoptions, warrants andrights(1)Number of securitiesremaining available forfuture issuance underequity compensation plans(excluding securitiesreflected in the firstcolumn(2))Equity compensation plans approved by security holders6,719,073 $30.44 4,609,